IRS Tax Refund Deadline Millions of Americans May Have Unclaimed COVIDEra Payments Meta Platforms Expands AI Private Chat Capabilities and Renewable Energy Portfolio US Retail Sales Surpass Expectations Amid Robust Consumer Demand Saregama India Shares Hold Steady Above Key Support Levels After Breakout Andy Burnhams Manchester Ethos Could a Mix of Collectivism and Entrepreneurialism Reshape UK Economic Policy BBVA Banco Frances Q1 Earnings Call Digital Expansion and Economic Headwinds in Focus LAC Q1 2026 Earnings NarrowerThanExpected Loss Highlights Progress on Thacker Pass LPX Q1 2026 Earnings Stellar EPS Surprise of 218 Highlights Operational Strength SBS Q1 2026 Earnings Modest EPS Beat Amidst Operational Efficiency Gains FatPipe Inc Q1 2026 Earnings Positive EPS Reported Amidst Market Skepticism AVGO Q1 2026 Earnings EPS Misses Estimates Stock Edges Lower CHAI Q4 2025 Earnings Massive Earnings Miss Highlights Ongoing Challenges ANI Pharmaceuticals Holds Steady Near Support as Trading Volume Eases KB Financial Group KB Faces Selling Pressure as Shares Dip 137 TOP Ships Inc TOPS Surges 6 Testing Key Resistance at 105 Sunshine Biopharma SBFM Slides 116 as Support at 044 Comes into Focus Sylvamo Corporation SLVM Holds Steady With Slight Decline as Support Levels Remain Intact SpaceX Successfully Launches Starship on Second Attempt Advancing Reusable Rocket Program BRC Q1 2026 Earnings EPS Beats Estimates by 104 as Stock Rises 35 MBVIW Warrants Hold Steady at 040 as Merger Timeline Watchers Await Catalyst Microbot Medical Inc MBOT Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Market Reaction Kars4Kids Faces California Ad Ban Over Charity Affiliation Disclosure Financial Implications RXO Reports Continued Surge in Truckload Spot Market During Second Quarter Nelnet Q1 2026 Earnings EPS Falls Short of Estimates as Revenue Details Remain Opaque PRGS Q1 2026 Earnings Modest EPS Beat Fails to Lift Shares LOVE Q1 2026 Earnings EPS Surges Past Estimates Stock Edges Higher BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development